Abstract:OBJECTIVE:To explore the effect of the glucagon-like peptide-1 receptor agonist exenatide on coagulation function and platelet aggregation in patients with type 2 diabetes mellitus (T2DM).METHODS:Thirty patients with newly diagnosed T2DM were enrolled as the case group, and 30 healthy people with matching age and sex were selected as the control group. Patients in the case group received exenatide treatment for 8 weeks. The general clinical data and biochemical indicators of all subjects were collected; and their peripheral blood platelet count, coagulation index, nitric oxide (NO), platelet membrane glycoprotein (CD62p), platelet activation complex-1 (PAC-1) and platelet aggregation induced by collagen, epinephrine (EPI), arachidonic acid (AA), and adenosine diphosphate (ADP) were detected.RESULTS:The fibrinogen, CD62p, PAC-1, and platelet aggregation rates of the case group (pretreatment) are higher than those in the control group (EPI 77.90±6.31 vs 60.15±5.37, ADP 52.89±9.36 vs 47.90±6.16, and AA 76.09±3.14 vs.55.18±3.55); and the NO level is lower in the case group than in the control group (p<0.05, respectively). After 8 weeks of exenatide treatment in the case group, the CD62p, PAC-1, and platelet aggregation rates were lower than before the treatment (EPI: 61.96±8.94 vs 77.90±6.31 and AA: 50.98±6.73 vs 76.09±3.14); and the NO level was higher than before the treatment (p<0.05, respectively). Pearson correlation analysis showed that the changes in platelet aggregation rates (Δ EPI and ΔAA) of the patients in the case group after 8 weeks of exenatide treatment were positively correlated with the changes in body mass index, waist circumference, weight, blood lipids, fasting plasma glucose, haemoglobin A1c, fibrinogen, CD62p, and PAC-1 and negatively correlated with the changes in high-density lipoprotein and NO (p<0.05). Multiple linear regression analysis showed that the changes in NO, CD62p and PAC-1 were independent risk factors affecting the changes in platelet aggregation rates.CONCLUSION:The GLP-1R agonist exenatide can inhibit the activation state of platelets in patients with T2DM and inhibit thrombosis, which is beneficial to reduce the risk of cardiovascular events.

Exenatide Exerts Direct Protective Effects on Endothelial Cells Through the AMPK/Akt/eNOS Pathway in a GLP-1 Receptor-Dependent Manner.

Exenatide Prevents High-Glucose-induced Damage of Retinal Ganglion Cells Through a Mitochondrial Mechanism

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways

Effects of Exenatide Therapy on Insulin Resistance in the Skeletal Muscles of High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats.

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and During Hyperinsulinemic-Euglycemic Clamp.

GLP-1 Receptor Agonist Improves Mitochondrial Energy Status and Attenuates Nephrotoxicity In Vivo and In Vitro

Effects of Exenatide on Lipid Metabolism of Adipose Tissue in Diabetic Rats

Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes

Non-targeted Metabolomic Analysis Predicts the Therapeutic Effects of Exenatide on Endothelial Injury in Patients with Type 2 Diabetes.

2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway

Db121025 1697..1708

1938-P: GLP-1 Receptor Agonist Ameliorates Intramyocellular Lipid Deposition Without Weight Loss by Activating AMPK

Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice

Exenatide Mitigates Inflammation and Hypoxia along with Improved Angiogenesis in Obese Fat Tissue.

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

A GLP-1 analog lowers ER stress and enhances protein folding to ameliorate homocysteine-induced endothelial dysfunction

The Cardiovascular Effect of Glucagon-like Peptide-1 Receptor Agonists

Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury In Diabetes Via A Camp/Pka/Rho-Dependent Mechanism

Comparing the Effects of Twice-Daily Exenatide and Insulin on Renal Function in Patients with Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Controlled Trial.

Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes